Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Abbott Labs (ABT - Analyst Report) recently presented phase III data on its blockbuster drug, Humira, from two studies. While ABILITY-2 is being conducted in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS), ABILITY-1 is being conducted in patients with axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

Abbott Labs said that 39.3% of patients in the Humira arm achieved the primary endpoint compared to 19.8% of patients on placebo.  The primary endpoint was an improvement of at least 40% in the peripheral SpA response criteria (PSpARC 40).

Meanwhile, results from the ABILITY-1 study showed that 36.3% of patients in the Humira arm achieved ASAS 40 compared to 14.9% of patients in the placebo arm at 12 weeks.

Abbott Labs presented these results at the European League Against Rheumatism (EULAR) 2012 Congress.

Humira is a key product in Abbott Labs' pharmaceutical products portfolio. Humira is approved for several indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease. Humira sales increased 21.1% to $7.9 billion in 2011. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan should help the product to continue contributing significantly to the top-line.

Moreover, approval for additional indications would boost peak sales forecasts for the drug significantly. Earlier this year, Humira gained approval for an additional indication in the EU. The European Commission cleared Humira for treating adults suffering from moderately to severely active ulcerative colitis (UC). The product gained approval for use in patients who did not respond satisfactorily to standard drugs for UC treatment.

Other players in the anti-inflammatory market include Pfizer/Amgen’s (PFE - Analyst Report)/(AMGN - Analyst Report) Enbrel, Johnson & Johnson/Merck’s (JNJ - Analyst Report)/(MRK - Analyst Report) Remicade and Simponi.

We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term ‘Hold’ rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%